Get started
MiNK Therapeutics, Inc.MiNK Therapeutics, Inc.MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials
News Ideas Technicals Forecast

INKT fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

INKT does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company